Market News & Trends
Edge Therapeutics Reports Positive Top-Line Phase I/II NEWTON Trial Results
Edge Therapeutics, Inc. recently announced that its recently completed North American Phase I/II NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage)…
Charleston Laboratories Announces Completion of Second Phase III Trial
Charleston Laboratories, Inc. recently announced completion of their second Phase III clinical study on CL-108, a novel bi-layered tablet containing 7.5 mg of hydrocodone and…
VBL Announces First Patient Dosed In Pivotal Phase III Trial
VBL Therapeutics recently announced that the first patient has been dosed in the company's GLOBE Study, a pivotal Phase III trial of VB-111, an intravenously…
Janus Biotherapeutics Enters Collaboration With Roche
Janus Biotherapeutics recently announced it has entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the…
NanoViricides Reports Dramatic Effects of Topical Anti-Herpes Treatment Were Reproduced Once Again
NanoViricides, Inc. recently reported that the dramatic improvements in clinical symptoms associated with herpes simplex virus infection were reproduced in an animal model in a…
BioClin Therapeutics Initiates Phase II Clinical Trial for Urothelial Cell Carcinoma
BioClin Therapeutics, Inc. recently announced it has initiated a Phase II clinical study of B-701, an anti-FGFR3 antibody being investigated for the treatment of locally…
Pluristem in Key Discussions With Europe’s Adaptive Pathways Group on Phase II Protocol
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, recently announced it has conducted detailed discussions with the European Adaptive Pathways Discussion Group…
Corbion & MedinCell Form Strategic Joint Venture
The joint venture, CM Biomaterials, will sell the PEG / PLA co-polymers to MedinCell partners who license the MedinCell technology (BEPO). Manufacturing of the polymers…
HERMES PHARMA Brings Easy-to-Swallow Medicines to US Market
HERMES PHARMA, Europe's largest developer and manufacturer of user-friendly solid oral dosage forms, recently announced plans to ramp up its expansion into the US market.…
Proteon Therapeutics Initiates Second Phase III Clinical Study
Proteon Therapeutics Inc. recently announced that the first patient has been treated in a second Phase III clinical study of investigational vonapanitase (formerly PRT-201), the…